Immunomedics Downgraded At Jefferies, Firm Removes Epratuzumab Revenues From Model
July 29, 2015 at 09:58 AM EDT
In a report published Wednesday, Jefferies analyst Chris Howerton downgraded the rating on Immunomedics, Inc. (NASDAQ: IMMU) from Buy to ...
